Alfresa Holdings Corporation (JP:2784)
:2784
Want to see JP:2784 full AI Analyst Report?
Top Page
Alfresa Holdings
(2784)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥2,568.00
▲(1.78% Upside)
Action:Downgraded
Date:05/17/26
The score is driven by attractive valuation (low P/E and a solid dividend) and a conservative, low-debt balance sheet. These positives are tempered by uneven cash-flow consistency and currently weak technical momentum (negative MACD and trading below key moving averages).
Positive Factors
Conservative balance sheet
Low leverage and a stronger equity base provide durable financial flexibility for a distribution business that needs to hold inventory and fund working capital. This footing reduces default risk and supports strategic investments or M&A without pressuring cash flow in downturns.
Negative Factors
Very thin operating and net margins
Extremely narrow margins leave earnings highly sensitive to cost increases, reimbursement shifts or pricing competition. With limited margin buffer, small adverse changes can meaningfully reduce profitability and constrain reinvestment or dividend capacity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a stronger equity base provide durable financial flexibility for a distribution business that needs to hold inventory and fund working capital. This footing reduces default risk and supports strategic investments or M&A without pressuring cash flow in downturns.
Read all positive factors
Alfresa Holdings (2784) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥423.73B
Dividend Yield2.69%
Average Volume (3M)354.02K
Price to Earnings (P/E)11.0
Beta (1Y)0.65
Revenue Growth4.83%
EPS Growth56.24%
CountryJP
Employees12,517
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)150.82
Shares Outstanding191,300,000
10 Day Avg. Volume331,350
30 Day Avg. Volume354,016
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.91
Price to Sales (P/S)0.15
P/FCF Ratio28.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,400.00Price Target Upside-4.88% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)155.59
Revenue Forecast (FY)¥3.19T
Alfresa Holdings Business Overview & Revenue Model
Company Description
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ...
How the Company Makes Money
Alfresa Holdings primarily makes money by acting as a wholesaler/distributor in the healthcare supply chain. Its main revenue stream is the sale of prescription pharmaceuticals purchased from manufacturers and sold to customers such as hospitals, ...
Alfresa Holdings Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.00T | 3.10T | 2.96T | 2.86T | 2.70T | 2.59T |
| Gross Profit | 215.35B | 217.88B | 202.71B | 196.36B | 182.26B | 178.31B |
| EBITDA | 53.20B | 51.07B | 53.20B | 51.98B | 43.45B | 41.92B |
| Net Income | 27.96B | 41.75B | 27.39B | 29.56B | 25.79B | 32.18B |
Balance Sheet | ||||||
| Total Assets | 1.48T | 1.51T | 1.44T | 1.45T | 1.34T | 1.30T |
| Cash, Cash Equivalents and Short-Term Investments | 180.61B | 193.07B | 177.09B | 213.76B | 160.12B | 180.44B |
| Total Debt | 30.60B | 35.62B | 35.55B | 34.94B | 3.85B | 5.04B |
| Total Liabilities | 999.83B | 999.11B | 957.63B | 967.76B | 851.51B | 832.15B |
| Stockholders Equity | 478.32B | 507.36B | 481.79B | 479.60B | 488.09B | 471.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 16.11B | -10.87B | 73.64B | -9.63B | 21.54B |
| Operating Cash Flow | 0.00 | 38.57B | 5.64B | 86.38B | 13.09B | 36.55B |
| Investing Cash Flow | 0.00 | -8.72B | -24.92B | -14.22B | -20.54B | 2.30B |
| Financing Cash Flow | 0.00 | -14.05B | -23.53B | -19.70B | -12.92B | -29.15B |
Alfresa Holdings Technical Analysis
Negative
2523.00
Price Trends
2425.11
Negative
2457.45
Negative
2323.23
Negative
Market Momentum
-45.52
Positive
34.74
Neutral
23.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2784, the sentiment is Negative. The current price of 2523 is above the 20-day moving average (MA) of 2355.50, above the 50-day MA of 2425.11, and above the 200-day MA of 2323.23, indicating a bearish trend. The MACD of -45.52 indicates Positive momentum. The RSI at 34.74 is Neutral, neither overbought nor oversold. The STOCH value of 23.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2784.
Alfresa Holdings Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥301.20B | 10.88 | 8.60% | 1.60% | 3.61% | 20.83% | |
69 Neutral | ¥514.12B | 14.22 | 6.39% | 2.27% | 3.98% | 7.00% | |
68 Neutral | ¥435.07B | 14.57 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥358.08B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥423.73B | 11.01 | 6.92% | 2.69% | 4.83% | 56.24% | |
66 Neutral | ¥563.64B | 17.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
JP:2784
Alfresa Holdings
2,220.50
356.13
19.10%
JP:7459
Medipal Holdings
2,834.00
638.43
29.08%
JP:9989
Sundrug Co
3,721.00
-652.42
-14.92%
JP:7649
Sugi Holdings Co
2,990.50
-40.50
-1.34%
JP:9987
Suzuken Co
5,306.00
193.59
3.79%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,745.00
423.78
12.76%
Alfresa Holdings Corporate Events
Alfresa Launches ¥15 Billion Share Buyback via Accelerated Repurchase
May 15, 2026
Alfresa Holdings has approved a share repurchase of up to 6,307,800 common shares, representing about 3.5% of its outstanding stock, for a total of approximately ¥15 billion to enhance capital efficiency and boost shareholder returns. The buy...
Alfresa to Shift Legal Public Notices From Newspaper to Digital Format
May 15, 2026
Alfresa Holdings will seek shareholder approval at its 23rd Ordinary General Meeting on June 24, 2026, to revise its Articles of Incorporation and shift its method of corporate public notices from newspaper publication in the Nihon Keizai Shimbun ...
Alfresa Profit Jumps on Higher Sales as Outlook Turns Cautious for FY 2027
May 15, 2026
Alfresa Holdings reported consolidated net sales of ¥3,104.1 billion for the fiscal year ended March 31, 2026, up 4.8% year on year, while operating and ordinary profit declined slightly, and profit attributable to owners of parent surged 52....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.